> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Platform Technology OK for Sarepta Vector
- URL: https://www.fdaweb.com/fda-platform-technology-ok-for-sarepta-vector/
- Published: 2025-06-05T12:00:00.000Z
- Updated: 2026-09-14T15:13:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159308

FDA has granted platform technology designation for Sarepta Therapeutics’ rAAVrh74 viral vector used in its investigational SRP-9003 (bidridistrogene xeboparvovec) to treat limb-girdle muscular dystrophy type 2E/R4\. A company [statement](https://investorrelations.sarepta.com/news-releases/news-release-details/us-fda-grants-platform-technology-designation-viral-vector-used?ref=fdaweb.com) says it is one of the first programs to receive the FDA designation.

To be eligible for the designation, Sarepta says, a technology must be well-understood and reproducible and can support the development of multiple drugs or biologics.

SRP-9003 is described as an investigational gene therapy designed to be systemically and robustly delivered to skeletal, diaphragm, and cardiac muscle.